$SGRY
Surgery Partners, Inc. Stock $sgry

$sgry Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000163883317000044 Filed on November 09, 2017

Income Statement

Concept	2017 Q4	2017 Q3
Revenue	$460.3M	$132.3M
YoY Change	50.44%	-53.21%
Cost Of Revenue	$338.7M	$102.9M
YoY Change	58.09%	-48.89%
Gross Profit	$121.6M	$29.33M
YoY Change	32.57%	-63.91%
Gross Profit Margin	26.42%	22.18%
Selling, General & Admin	$51.20M	$45.00M
YoY Change	28.64%	22.62%
% of Gross Profit	42.09%	153.41%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$18.40M	$3.330M
YoY Change	73.58%	-65.72%
% of Gross Profit	15.13%	11.35%
Operating Expenses	$69.70M	$120.3M
YoY Change	38.29%	-49.83%
Operating Profit	$51.94M	$11.93M
YoY Change	25.6%	-72.17%
Interest Expense	-$30.30M	-$15.88M
YoY Change	26.78%	-40.01%
% of Operating Profit	-58.33%	-133.18%
Other Income/Expense, Net	$25.50M	$17.40M
YoY Change	3542.86%	-524.39%
Pretax Income	$72.80M	-$2.859M
YoY Change	70.49%	-122.62%
Income Tax	$7.900M	-$211.0K
% Of Pretax Income	10.85%
Net Earnings	-$32.18M	-$9.140M
YoY Change	-290.82%	290.93%
Net Earnings / Revenue	-6.99%	-6.91%
Basic Earnings Per Share	-$0.83	-$0.57
Diluted Earnings Per Share	-$0.83	-$0.57
COMMON SHARES
Basic Shares Outstanding	48.77M shares	48.31M shares
Diluted Shares Outstanding		48.31M shares

Balance Sheet

Concept	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$174.9M	$199.7M
YoY Change	150.93%	261.78%
Cash & Equivalents	$174.9M	$214.2M
Short-Term Investments
Other Short-Term Assets	$38.50M	$15.48M
YoY Change	239.58%	49.04%
Inventory	$44.95M	$44.52M
Prepaid Expenses	$16.84M	$18.42M
Receivables	$288.0M	$271.1M
Other Receivables	$14.20M	$19.90M
Total Short-Term Assets	$563.2M	$573.7M
YoY Change	55.61%	74.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$398.5M	$388.7M
YoY Change	95.06%	94.74%
Goodwill	$3.347B	$3.269B
YoY Change	115.2%	113.48%
Intangibles	$58.91M	$56.75M
YoY Change	22.67%	16.59%
Long-Term Investments	$77.70M	$67.50M
YoY Change	96.71%	71.32%
Other Assets	$48.67M	$19.13M
YoY Change	196.11%	38.34%
Total Long-Term Assets	$4.060B	$4.028B
YoY Change	108.93%	109.8%
TOTAL ASSETS
Total Short-Term Assets	$563.2M	$573.7M
Total Long-Term Assets	$4.060B	$4.028B
Total Assets	$4.623B	$4.602B
YoY Change	100.56%	104.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$84.71M	$73.25M
YoY Change	70.22%	64.78%
Accrued Expenses	$122.9M	$99.30M
YoY Change	73.1%	42.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$58.70M	$48.50M
YoY Change	111.15%	66.67%
Total Short-Term Liabilities	$303.0M	$275.0M
YoY Change	62.27%	53.94%
LONG-TERM LIABILITIES
Long-Term Debt	$2.252B	$2.562B
YoY Change	53.51%	81.58%
Other Long-Term Liabilities	$222.5M	$116.8M
YoY Change	191.72%	33.59%
Total Long-Term Liabilities	$222.5M	$116.8M
YoY Change	191.72%	33.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$303.0M	$275.0M
Total Long-Term Liabilities	$222.5M	$116.8M
Total Liabilities	$525.5M	$391.8M
YoY Change	99.81%	47.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.32M	-$9.140M
YoY Change	-86.73%	-97.22%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$654.7M	$695.4M
YoY Change
Total Liabilities & Shareholders Equity	$4.623B	$4.602B
YoY Change	100.56%	104.64%

Cashflow Statement

Concept	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$32.18M	-$9.140M
YoY Change	-290.82%	290.93%
Depreciation, Depletion And Amortization	$18.40M	$3.330M
YoY Change	73.58%	-65.72%
Cash From Operating Activities	$54.40M	-$1.222M
YoY Change	68.42%	-106.47%
INVESTING ACTIVITIES
Capital Expenditures	-$9.000M	$1.840M
YoY Change	-15.89%	-123.0%
Acquisitions		$1.163M
YoY Change
Other Investing Activities	-$26.90M	$0.00
YoY Change	37.24%	-100.0%
Cash From Investing Activities	-$35.80M	-$3.003M
YoY Change	18.15%	-85.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$3.609M
YoY Change
Cash From Financing Activities	-43.40M	-$10.28M
YoY Change	-447.2%	-277.24%
NET CHANGE
Cash From Operating Activities	54.40M	-$1.222M
Cash From Investing Activities	-35.80M	-$3.003M
Cash From Financing Activities	-43.40M	-$10.28M
Net Change In Cash	-24.80M	-$14.51M
YoY Change	-271.03%	-492.03%
FREE CASH FLOW
Cash From Operating Activities	$54.40M	-$1.222M
Capital Expenditures	-$9.000M	$1.840M
Free Cash Flow	$63.40M	-$3.062M
YoY Change	47.44%	-111.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2017Q3	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2633000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001638833
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48769296	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Surgery Partners, Inc.
CY2017Q3	sgry	Amortizationof Unfavorable Lease Liability AmortizationofUnfavorableLeaseLiability	27000	USD
CY2017Q3	sgry	Business Acquisition Contingent Acquisition Compensation Liability Current BusinessAcquisitionContingentAcquisitionCompensationLiabilityCurrent	7866000	USD
CY2017Q3	sgry	Business Combination Contingent Acquisition Expense BusinessCombinationContingentAcquisitionExpense	605000	USD
CY2017Q3	sgry	Business Combination Gain Loss On Acquisition Escrow BusinessCombinationGainLossOnAcquisitionEscrow	0	USD
	sgry	Business Combination Integration Related Costs And Merger Costs BusinessCombinationIntegrationRelatedCostsAndMergerCosts	2400000	USD
CY2017Q3	sgry	Business Combination Integration Related Costs And Merger Costs BusinessCombinationIntegrationRelatedCostsAndMergerCosts	3457000	USD
CY2017Q3	sgry	Business Combination Practice Acquisition Costs BusinessCombinationPracticeAcquisitionCosts	606000	USD
	sgry	Business Combination Practice Acquisition Costs BusinessCombinationPracticeAcquisitionCosts	2100000	USD
CY2017Q3	sgry	Business Combination Practice Acquisition Costs BusinessCombinationPracticeAcquisitionCosts	474000	USD
CY2016Q3	sgry	Business Combination Practice Acquisition Costs BusinessCombinationPracticeAcquisitionCosts	607000	USD
	sgry	Business Combination Practice Acquisition Costs BusinessCombinationPracticeAcquisitionCosts	2200000	USD
CY2017Q3	sgry	Debt Instrument Prepayment Penalty Amount DebtInstrumentPrepaymentPenaltyAmount	0	USD
CY2017Q3	sgry	Deferred Income Tax Liability Gain On Amendment Of Liability DeferredIncomeTaxLiabilityGainOnAmendmentOfLiability	1100000	USD
CY2017Q3	sgry	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	14842000	USD
CY2017Q3	sgry	Escrow Deposit Current EscrowDepositCurrent	4571000	USD
CY2017Q3	sgry	Escrow Deposit Noncurrent EscrowDepositNoncurrent	19600000	USD
CY2017Q3	sgry	Escrow Liability Current EscrowLiabilityCurrent	4571000	USD
CY2017Q3	sgry	Escrow Liability Noncurrent EscrowLiabilityNoncurrent	19600000	USD
CY2017Q3	sgry	Gain Loss On Amendment To Tax Receivable Agreement GainLossOnAmendmentToTaxReceivableAgreement	1098000	USD
CY2017Q3	sgry	Incentive Payments Recognizedfor Certain Hospitalsand Physician Practices That Demonstrate Meaningful Useof Certified Electronic Health Record Technology IncentivePaymentsRecognizedforCertainHospitalsandPhysicianPracticesThatDemonstrateMeaningfulUseofCertifiedElectronicHealthRecordTechnology	-7000	USD
CY2017Q3	sgry	Increaseof Revenueas Resultof Changesin Estimatesto Thirdparty Settlements Relatedto Prior Years IncreaseofRevenueasResultofChangesinEstimatestoThirdpartySettlementsRelatedtoPriorYears	0	USD
CY2017Q3	sgry	Intangible Assets Professional Recruitment Expense IntangibleAssetsProfessionalRecruitmentExpense	38000	USD
CY2017Q3	sgry	Lease Obligation Noncurrent LeaseObligationNoncurrent	90052000	USD
CY2017Q3	sgry	Medical Malpractice Liability Noncurrent MedicalMalpracticeLiabilityNoncurrent	13453000	USD
CY2017Q3	sgry	Non Controlling Interest Acquisitions And Disposals Of Interests Held By Non Controlling Interest Holders Net NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet	-19000	USD
CY2017Q3	sgry	Number Of Surgical Facilities Owned NumberOfSurgicalFacilitiesOwned	124	surgical_facility
CY2017Q3	sgry	Numberof Surgical Facilities Owned Consolidated NumberofSurgicalFacilitiesOwnedConsolidated	109	surgical_facility
CY2017Q3	sgry	Numberof Surgical Facilities Owned Majority Interest NumberofSurgicalFacilitiesOwnedMajorityInterest	85	surgical_facility
CY2017Q3	sgry	Optical Products Receivable OpticalProductsReceivable	8369000	USD
CY2017Q3	sgry	Redeemable Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	730000	USD
CY2017Q3	sgry	Redeemable Noncontrolling Interest Increase Decrease From Redemptions Or Purchase Of Interests RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests	91000	USD
CY2017Q3	sgry	Tax Receivable Agreement Expense TaxReceivableAgreementExpense	0	USD
CY2017Q3	sgry	Tax Receivable Agreement Liability Current TaxReceivableAgreementLiabilityCurrent	837000	USD
CY2017Q3	sgry	Tax Receivable Agreement Liability Noncurrent TaxReceivableAgreementLiabilityNoncurrent	68148000	USD
CY2017Q3	sgry	Third Party Settlements Payable Current ThirdPartySettlementsPayableCurrent	1400000	USD
CY2017Q3	sgry	Variable Interest Entity Numberof Facilities VariableInterestEntityNumberofFacilities	3	Anesthesia_Practice
CY2017Q3	sgry	Variable Interest Entity Numberof Facilities VariableInterestEntityNumberofFacilities	3	Practice
CY2017Q3	sgry	Variable Interest Entity Numberof Facilities VariableInterestEntityNumberofFacilities	5	surgical_facility
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	73251000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	271140000	USD
CY2017Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	10287000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	2729000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	704054000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2648000	USD
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	102924000	USD
CY2017Q3	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	15566000	USD
CY2017Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1683000	USD
CY2017Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3690000	USD
CY2017Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	-103000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	271000	USD
CY2017Q3	us-gaap	Assets Assets	4601854000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	573659000	USD
CY2017Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	5033000	USD
	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	5600000	USD
CY2017Q3	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	2983000	USD
CY2017Q3	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	3000000	USD
CY2016Q3	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	1900000	USD
	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	6400000	USD
CY2017Q3	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	2300000	USD
CY2017Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	16340000	USD
CY2017Q3	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	19200000	USD
CY2017Q3	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	700000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	199701000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	214206000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14505000	USD
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48769296	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48769296	shares
CY2017Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	488000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9140000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	6492000	USD
CY2017Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0	USD
CY2017Q3	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	1804000	USD
CY2017Q3	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	1804000	USD
CY2017Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0	USD
CY2017Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-465000	USD
CY2017Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	120500000	USD
CY2017Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	209207000	USD
CY2017Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3330000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.38
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	42439000	USD
CY2017Q3	us-gaap	Estimated Insurance Recoveries EstimatedInsuranceRecoveries	9100000	USD
CY2017Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	253000	USD
CY2017Q3	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	66000	USD
CY2017Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-333000	USD
CY2017Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-16400000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7777000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	3270309000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	3269225000	USD
CY2017Q3	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1214000	USD
CY2017Q3	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-130000	USD
CY2017Q3	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	0	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2859000	USD
CY2017Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	712000	USD
CY2017Q3	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	203000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-211000	USD
CY2017Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	8618000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2795000	USD
CY2017Q3	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	2919000	USD
CY2017Q3	us-gaap	Insurance Receivable For Malpractice Current InsuranceReceivableForMalpracticeCurrent	2837000	USD
CY2017Q3	us-gaap	Insurance Receivable For Malpractice Noncurrent InsuranceReceivableForMalpracticeNoncurrent	6835000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56507000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56750000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-15883000	USD
CY2017Q3	us-gaap	Interest Payable Current InterestPayableCurrent	23777000	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	44523000	USD
CY2017Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	64427000	USD
CY2017Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	41784000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4601854000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	275012000	USD
CY2017Q3	us-gaap	Long Term Accounts Notes And Loans Receivable Net Noncurrent LongTermAccountsNotesAndLoansReceivableNetNoncurrent	2853000	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	2144862000	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	48472000	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	2193334000	USD
CY2017Q3	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	8618000	USD
CY2017Q3	us-gaap	Minority Interest MinorityInterest	683733000	USD
CY2017Q3	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	5714000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10280000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3003000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1222000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-9140000	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6492000	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1054000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27339000	USD
CY2017Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-3702000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2017Q3	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	32	state
CY2017Q3	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	7893000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	120332000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	11926000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	6858000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	33076000	USD
CY2017Q3	us-gaap	Other Assets Current OtherAssetsCurrent	15482000	USD
CY2017Q3	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	4847000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19133000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2017Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	8000000	USD
CY2017Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	106279000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	116799000	USD
CY2017Q3	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	0	USD
CY2017Q3	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	3597000	USD
CY2017Q3	us-gaap	Payables To Customers PayablesToCustomers	15087000	USD
CY2017Q3	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4000	USD
CY2017Q3	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	6444000	USD
CY2017Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2017Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1163000	USD
CY2017Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1840000	USD
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	53724000	USD
CY2017Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18418000	USD
CY2017Q3	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2017Q3	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2017Q3	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	30000	USD
CY2017Q3	us-gaap	Professional Fees ProfessionalFees	11254000	USD
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-2648000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross Excluding Capital Leased Assets PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets	391426000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	388697000	USD
CY2017Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3690000	USD
CY2017Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	271416000	USD
CY2017Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	271001000	USD
CY2017Q3	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Redemption Value RedeemableNoncontrollingInterestEquityPreferredRedemptionValue	326882000	USD
CY2017Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3609000	USD
CY2017Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	315000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9140000	USD
CY2017Q3	us-gaap	Revenues Revenues	132258000	USD
CY2017Q3	us-gaap	Security Deposit SecurityDeposit	2794000	USD
CY2017Q3	us-gaap	Self Insurance Reserve SelfInsuranceReserve	16600000	USD
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1683000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	695402000	USD
CY2017Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1379135000	USD
CY2017Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1405086000	USD
CY2017Q3	us-gaap	Supplies Expense SuppliesExpense	35028000	USD
CY2017Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	6731000	USD
CY2017Q3	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	2633000	USD
CY2017Q3	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	15566000	USD
CY2017Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	15566000	USD
CY2017Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	326882000	USD
CY2017Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	310000000	USD
CY2017Q3	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1316000	USD
CY2017Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	2633000	USD
CY2017Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48314746	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48314746	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Surgery Partners, Inc.</font><font style="font-family:inherit;font-size:9pt;">,</font><font style="font-family:inherit;font-size:10pt;"> a </font><font style="font-family:inherit;font-size:9pt;">Delaware corporation (together with its subsidiaries, the “Company”), was formed on April 2, 2015, as a holding company for the purpose of facilitating an initial public offering (the “IPO”) of shares of common stock. Prior to September 30, 2015, the Company conducted business through Surgery Center Holdings, Inc. and its subsidiaries. Surgery Center Holdings, LLC was and is the sole indirect owner of the equity interests of Surgery Center Holdings, Inc. and has no other material assets. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">On September 30, 2015, Surgery Partners, Inc. became the direct parent and sole member of Surgery Center Holdings, LLC (the "Reorganization"). In the Reorganization, all of the equity interests held by the pre-IPO owners of Surgery Center Holdings, LLC were contributed to Surgery Partners, Inc. in exchange for </font><font style="font-family:inherit;font-size:9pt;">33,871,990</font><font style="font-family:inherit;font-size:9pt;"> shares of common stock of Surgery Partners, Inc. and certain rights to additional payments under a tax receivable agreement. After giving effect to the Reorganization, Surgery Partners, Inc. is a holding company, and its sole material asset is an equity interest in Surgery Center Holdings, LLC. On October 1, 2015, the Company completed its IPO of </font><font style="font-family:inherit;font-size:9pt;">14,285,000</font><font style="font-family:inherit;font-size:9pt;"> shares of common stock at an offering price of </font><font style="font-family:inherit;font-size:9pt;">$19.00</font><font style="font-family:inherit;font-size:9pt;"> per share.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">On August 31, 2017, the Company completed its acquisition of NSH Holdco, Inc. (“NSH”). Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 9, 2017, by and among the Company, SP Merger Sub, Inc., a wholly owned subsidiary of the Company, NSH, and IPC / NSH, L.P. (solely in its capacity as sellers’ representative), as amended by that certain Letter Amendment, dated as of July 7, 2017 (as amended, the “NSH Merger Agreement”), SP Merger Sub, Inc. merged with and into NSH with NSH continuing as the surviving corporation and a wholly owned subsidiary of Surgery Center Holdings, Inc. (the “NSH Merger”). Also on August 31, 2017, (i) the Company completed the sale and issuance of </font><font style="font-family:inherit;font-size:9pt;">310,000</font><font style="font-family:inherit;font-size:9pt;"> shares of the Company's preferred stock, par value </font><font style="font-family:inherit;font-size:9pt;">$0.01</font><font style="font-family:inherit;font-size:9pt;"> per share, designated as </font><font style="font-family:inherit;font-size:9pt;">10.00%</font><font style="font-family:inherit;font-size:9pt;"> Series A Convertible Perpetual Participating Preferred Stock (the “Series A Preferred Stock”) to BCPE Seminole Holdings LP (“Bain”), an affiliate of Bain Capital Private Equity, at a purchase price of </font><font style="font-family:inherit;font-size:9pt;">$1,000</font><font style="font-family:inherit;font-size:9pt;"> per share in cash (the “Preferred Private Placement”) pursuant to the Securities Purchase Agreement, dated as of May 9, 2017, by and between the Company and Bain (the “Preferred Stock Purchase Agreement”), and (ii) Bain completed its purchase of </font><font style="font-family:inherit;font-size:9pt;">26,455,651</font><font style="font-family:inherit;font-size:9pt;"> shares (the “Purchased Shares”) of the Company's common stock, par value </font><font style="font-family:inherit;font-size:9pt;">$0.01</font><font style="font-family:inherit;font-size:9pt;"> per share (the “Common Stock”) from H.I.G. Surgery Centers, LLC (“H.I.G.”) at a purchase price of </font><font style="font-family:inherit;font-size:9pt;">$19.00</font><font style="font-family:inherit;font-size:9pt;"> per share in cash (the “Private Sale”) pursuant to the Stock Purchase Agreement, dated as of May 9, 2017, by and among the Company, Bain, H.I.G. and H.I.G. Bayside Debt & LBO Fund II L.P. (for the purposes stated therein) (the “Common Stock Purchase Agreement” and together with the NSH Merger Agreement, the Preferred Stock Purchase Agreement and the other agreements and documents executed in connection therewith, including the TRA (as defined in Note 2. “Significant Accounting Policies - Income Taxes and Tax Receivable Agreement”), the “Transaction Agreements”). As of August 31, 2017, the Purchased Shares represented approximately </font><font style="font-family:inherit;font-size:9pt;">54.2%</font><font style="font-family:inherit;font-size:9pt;"> of the Company’s outstanding Common Stock. As a result of the Preferred Private Placement and the Private Sale, Bain became the controlling stockholder of the Company, holding Series A Preferred Stock and Common Stock that collectively represent approximately </font><font style="font-family:inherit;font-size:9pt;">65.7%</font><font style="font-family:inherit;font-size:9pt;"> of the voting power of all classes of capital stock of the Company as of August 31, 2017, and H.I.G. and its affiliated investment funds no longer own any capital stock of the Company.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">In connection with the change of control effected by the Preferred Private Placement and the Private Sale, the Company elected to apply “pushdown” accounting by applying the guidance in Accounting Standards Codification Topic ("ASC") 805, </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Business Combinations</font><font style="font-family:inherit;font-size:9pt;">, including the recognition of the Company’s assets and liabilities at fair value as of August 31, 2017, and similarly recognizing goodwill calculated based on the terms of the transaction and the fair value of the new basis of net assets of the Company. Accordingly, the condensed consolidated financial statements of the Company for periods before and after August 31, 2017 reflect different bases of accounting, and the financial positions and results of operations of those periods are not comparable. Throughout the Company's condensed consolidated financial statements and the accompanying notes herein, periods prior to the change of control are identified as "Predecessor" and periods after the change of control are identified as "Successor."</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">As of </font><font style="font-family:inherit;font-size:9pt;">September 30, 2017</font><font style="font-family:inherit;font-size:9pt;"> (</font><font style="font-family:inherit;font-size:9pt;">Successor</font><font style="font-family:inherit;font-size:9pt;">), the Company owned and operated a national network of surgical facilities and ancillary services in </font><font style="font-family:inherit;font-size:9pt;">32</font><font style="font-family:inherit;font-size:9pt;"> states.  The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology</font><font style="font-family:inherit;font-size:10pt;"> ("</font><font style="font-family:inherit;font-size:9pt;">GI"), general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services, optical services and specialty pharmacy services. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> As of </font><font style="font-family:inherit;font-size:9pt;">September 30, 2017</font><font style="font-family:inherit;font-size:9pt;"> (</font><font style="font-family:inherit;font-size:9pt;">Successor</font><font style="font-family:inherit;font-size:9pt;">), the Company owned or operated a portfolio of </font><font style="font-family:inherit;font-size:9pt;">124</font><font style="font-family:inherit;font-size:9pt;"> surgical facilities, comprised of </font><font style="font-family:inherit;font-size:9pt;">104</font><font style="font-family:inherit;font-size:9pt;"> ASCs and </font><font style="font-family:inherit;font-size:9pt;">20</font><font style="font-family:inherit;font-size:9pt;"> surgical hospitals. The Company owns these facilities in partnership with physicians and, in some cases, healthcare systems in the markets and communities it serves. The Company owned a majority interest in </font><font style="font-family:inherit;font-size:9pt;">85</font><font style="font-family:inherit;font-size:9pt;"> of the surgical facilities and consolidated </font><font style="font-family:inherit;font-size:9pt;">109</font><font style="font-family:inherit;font-size:9pt;"> of these facilities for financial reporting purposes. In addition, the Company owned or operated a network of </font><font style="font-family:inherit;font-size:9pt;">60</font><font style="font-family:inherit;font-size:9pt;"> physician practices.</font></div></div>
	us-gaap	Revenue Recognition Sales Of Services RevenueRecognitionSalesOfServices	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Company recognizes revenues in the period in which the services are performed. Patient service revenues and receivables from third-party payors are recorded net of estimated contractual adjustments and allowances, which the Company estimates based on the historical trend of its cash collections and contractual write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Patient service revenues.</font><font style="font-family:inherit;font-size:9pt;"> The fee charged for healthcare procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient’s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized on the date of service, net of estimated contractual adjustments and discounts from third-party payors, including Medicare and Medicaid. Changes in estimated contractual adjustments and discounts are recorded in the period of change.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Other service revenues.</font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:9pt;"> Optical service revenues consist of product sales from the Company's optical laboratories as well as handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company's optical laboratories manufacture and distribute corrective lenses and eyeglasses to ophthalmologists and optometrists. Revenue is recognized when product is shipped, net of allowance for discounts. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which services are rendered.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All adjustments are of a normal, recurring nature. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001638833-17-000044-index-headers.html	Edgar Link	pending
0001638833-17-000044-index.html	Edgar Link	pending
0001638833-17-000044.txt	Edgar Link	pending
0001638833-17-000044-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
q3201710-qfiling.htm	Edgar Link	pending
q32017exhibit311.htm	Edgar Link	pending
q32017exhibit312.htm	Edgar Link	pending
q32017exhibit321.htm	Edgar Link	pending
q32017exhibit322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sgry-20170930.xml	Edgar Link	completed
sgry-20170930.xsd	Edgar Link	pending
sgry-20170930_cal.xml	Edgar Link	unprocessable
sgry-20170930_def.xml	Edgar Link	unprocessable
sgry-20170930_lab.xml	Edgar Link	unprocessable
sgry-20170930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SGRY
Surgery Partners, Inc. Stock $sgry

2017 Q4 Form 10-Q Financial Statement

#000163883317000044 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGRY Surgery Partners, Inc. Stock $sgry

2017 Q4 Form 10-Q Financial Statement

#000163883317000044 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGRY
Surgery Partners, Inc. Stock $sgry